DarioHealth Corp. (DRIO) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $7.56. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of DRIO = $167.44 (+2114.8% from the current price, the stock appears undervalued). Analyst consensus target is DRIO = $16 (+111.6% upside).
Valuation: DRIO trades at a trailing Price-to-Earnings (P/E) of 5.7 (S&P 500 average ~25).
Financials: revenue is $22M, -3.6%/yr average growth. Net income is $42M (loss), growing at +11.6%/yr. Net profit margin is -186.6% (negative). Gross margin is 56.6% (+21.7 pp trend).
Balance sheet: total debt is $32M against $68M equity (Debt-to-Equity (D/E) ratio 0.47, conservative). Current ratio is 3.73 (strong liquidity). Debt-to-assets is 28.8%. Total assets: $110M.
Analyst outlook: 8 / 8 analysts rate DRIO as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 48/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).
